At the news
? NEUTRALIMPACT 3/10 DEFA14A filed Mar 25, 2026 at 16:35 ET
Bristol-Myers Squibb Co filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting. The filing outlines proposals for shareholder vote, including the election of 11 directors, an advisory vote on executive compensation, approval of a new stock award plan, ratification of the auditor, and a shareholder proposal to make the board chair independent.
- Filing is a definitive proxy statement (DEFA14A) for the 2026 Annual Meeting
- Proposals include election of 11 director nominees
- Advisory vote on executive compensation
- Vote to approve the 2026 Stock Award and Incentive Plan
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access